-
Supreme Court rejects Teva's 'skinny label' case
The Supreme Court declined to hear Teva Pharmaceuticals USA's challenge to a $235 million award to GlaxoSmithKline in a patent dispute over a generic heart drug. -
FTC sues to block $28M Amgen-Horizon deal
The Federal Trade Commission has filed an injuction in federal court seeking to block Amgen's acquisition of fellow drugmaker Horizon Therapeutics. -
Ozempic alternatives concern health experts
Rising popularity of Novo Nordisk's Ozempic is making it more difficult to find, leaving some patients to turn to unauthorized alternatives, The New York Times reported May 16. -
Duke University begins universal flu vaccine trial
A universal flu vaccine that protects against all known strains of the virus — both seasonal and pandemic — is now undergoing a phase 1 trial at Duke University in Durham, N.C. -
Novartis taps new board members ahead of Sandoz spinoff
Drugmaker Novartis announced 10 members to its newly formed Sandoz board of directors May 15 ahead of its previously announced biosimilar spinoff. The Sandoz spinoff is an effort the company is making to keep a competitive pace with rising costs of brand name drugs. -
FDA greenlights menopause drug for hot flashes
The FDA on May 12 approved Astellas' Veozah — a once-a-day pill meant to treat hot flashes associated with menopause. -
Illinois pharmacists can now dispense birth control
Illinois' top public health leader issued a standing order May 11, allowing pharmacists in the state to dispense hormonal contraception. -
Alzheimer's drug may cost Medicare $5B annually, study estimates
Eisai and Biogen's new Alzheimer's drug Leqembi could cost Medicare an estimated $2 billion to $5 billion annually, according to a study published May 11 in JAMA Internal Medicine. -
COVID-19 allowances extended for pharmacists post-PHE
HHS officially extended COVID-19-era allowances for pharmacists through Dec. 31, 2024, after the agency said it planned to do so. -
Expanding pharmacist scopes: 4 hospital pharmacy leaders weigh in
As the American Medical Association pushes back on efforts to expand pharmacists' scopes of practice and lawmakers reintroduce bills aimed at increasing pharmacist roles, four leaders at hospitals and health systems weighed in on the debate. -
ASHP: Quality issues spurring more drug shortages
The American Society of Health-System Pharmacists said May 10 that quality issues at drug manufacturing sites are triggering more drug shortages. -
Pharmacist groups cheer for pharmacist scope bill
After five senators reintroduced a bill that looks to expand pharmacists' scope of practice and increase Medicare reimbursement for those extra services, pharmacist organizations applauded the proposed legislation. -
FDA approves 1st agitation drug for Alzheimer's patients
The FDA approved the first drug that treats agitation associated with Alzheimer's disease. -
Judge triples amount Eli Lilly must pay for violating False Claims Act
A federal judge in Illinois has tripled the amount Eli Lilly must pay after a jury found the pharmaceutical company guilty of violating the False Claims Act in August 2022, according to a May 9 report from Law360. -
Cisplatin resupply dates fluctuate again
For five months, drugmakers have reported changing resupply dates for cisplatin, an oncology treatment in short supply. The release date just changed again, according to the American Society of Health-System Pharmacists' latest update. -
Hackensack Meridian is 'reimagining' its pharmacy
The pharmacy department at Edison, N.J.-based Hackensack Meridian Health is planning for growth as the network reports a multimillion-dollar net loss. -
Ozempic, Wegovy could boost cancer-killing cells, small study suggests
A study of 20 people with obesity hinted at the possibility for semaglutide — the active ingredient in Type 2 diabetes drug Ozempic and weight-loss drug Wegovy — to increase the functionality of natural killer cells, which destroy cancerous cells. -
Post-markdown, GoodRx lists 31 insulin prices
After the three biggest insulin companies slashed their list prices, GoodRx refreshed its list of comparing costs among 31 generic and brand-name insulins. -
Novavax to lay off 25% of workforce
Novavax will lay off about 25 percent of its workforce and consolidate its facilities as part of a global restructuring to reduce costs, the drugmaker said May 9. -
UHS pharmacy leader: Speed of AI is akin to sending texts instead of letters
Artificial intelligence has already entered the pharmacy space, and it's past time to embrace the change in the workplace, according to the pharmacy leader of United Health Services hospitals in Johnson City, N.Y.
Page 42 of 50